Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach

KRAS inhibition maybe suitable for a tumor-agnostic drug development approach, but Amgen Inc. hasn't decided yet if that's the path it will take with AMG 510 based on the initial set of Phase I data for the company's first-in-class drug, which targets G12C mutations of the elusive KRAS oncogene.

Phase I data for AMG 510 were presented on 3 June at the American Society of Clinical Oncology (ASCO) meeting in Chicago. Amgen senior vice president of global development Elliott Levy told Scrip that the dose escalation stage of the study has been completed and the highest dose tested – 960mg taken once daily – has moved into dose expansion